title: Standard treatment option in stage III non-small-cell lung cancer: case against trimodal therapy and consolidation drug therapy.
abstract: Prospective randomized trials and meta-analyses established concurrent radiochemotherapy (RT-CHT) as standard treatment approach in patients with inoperable, locally advanced (stage IIIA and B) non-small-cell lung cancer (NSCLC). In patients with either clinically (c) or pathologically (p) staged disease (stage IIIA), including those with pN2 disease, trimodal therapy was also frequently practiced in the past and is currently still advocated by large cooperative groups and organizations. Similarly, consolidation CHT provided after concurrent RT-CHT was suggested to be feasible and effective in inoperable stage III NSCLC. Contrasting these practices and suggestions, there is no evidence that trimodal therapy in stage IIIA (clinically or pathologically staged) or consolidation CHT in inoperable stage III NSCLC plays any role in its treatment. In both cases, evidence clearly demonstrates that concurrent RT-CHT is of similar efficacy and less toxic, and it should be considered a standard treatment option for all patients with stage III NSCLC.
authors.affiliation: Insitute for Lung Diseases, Sremska Kamenica, Serbia; BioIRC Centre for Biomedical Research, Kragujevac, Serbia. Electronic address: nebareje@gmail.com.
authors.forename: Branislav
authors.initials: B
authors.lastname: Jeremić
mesh_terms: D002289:Carcinoma, Non-Small-Cell Lung / Q000473:pathology / Q000628:therapy*; D059248:Chemoradiotherapy / Q000009:adverse effects / Q000379:methods*; D003131:Combined Modality Therapy; D006801:Humans; D008175:Lung Neoplasms / Q000473:pathology / Q000628:therapy*; D009367:Neoplasm Staging; D016896:Treatment Outcome
keywords: Chemotherapy; Consolidation chemotherapy; Non–small-cell lung cancer; Radiotherapy; Surgery; Trimodal therapy